231 related articles for article (PubMed ID: 20635390)
1. A novel high-affinity human monoclonal antibody to mesothelin.
Ho M; Feng M; Fisher RJ; Rader C; Pastan I
Int J Cancer; 2011 May; 128(9):2020-30. PubMed ID: 20635390
[TBL] [Abstract][Full Text] [Related]
2. Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice.
Kim H; Gao W; Ho M
PLoS One; 2013; 8(11):e81919. PubMed ID: 24260587
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma.
Hassan R; Viner JL; Wang QC; Margulies I; Kreitman RJ; Pastan I
J Immunother; 2000; 23(4):473-9. PubMed ID: 10916757
[TBL] [Abstract][Full Text] [Related]
4. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity.
Feng Y; Xiao X; Zhu Z; Streaker E; Ho M; Pastan I; Dimitrov DS
Mol Cancer Ther; 2009 May; 8(5):1113-8. PubMed ID: 19417159
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin.
Fan D; Yano S; Shinohara H; Solorzano C; Van Arsdall M; Bucana CD; Pathak S; Kruzel E; Herbst RS; Onn A; Roach JS; Onda M; Wang QC; Pastan I; Fidler IJ
Mol Cancer Ther; 2002 Jun; 1(8):595-600. PubMed ID: 12479219
[TBL] [Abstract][Full Text] [Related]
6. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity.
Chowdhury PS; Viner JL; Beers R; Pastan I
Proc Natl Acad Sci U S A; 1998 Jan; 95(2):669-74. PubMed ID: 9435250
[TBL] [Abstract][Full Text] [Related]
7. A binding domain on mesothelin for CA125/MUC16.
Kaneko O; Gong L; Zhang J; Hansen JK; Hassan R; Lee B; Ho M
J Biol Chem; 2009 Feb; 284(6):3739-49. PubMed ID: 19075018
[TBL] [Abstract][Full Text] [Related]
8. Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer.
Kessler C; Pardo A; Tur MK; Gattenlöhner S; Fischer R; Kolberg K; Barth S
J Cancer Res Clin Oncol; 2017 Oct; 143(10):2025-2038. PubMed ID: 28667390
[TBL] [Abstract][Full Text] [Related]
9. New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA.
Onda M; Willingham M; Nagata S; Bera TK; Beers R; Ho M; Hassan R; Kreitman RJ; Pastan I
Clin Cancer Res; 2005 Aug; 11(16):5840-6. PubMed ID: 16115924
[TBL] [Abstract][Full Text] [Related]
10. Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer.
Bera TK; Williams-Gould J; Beers R; Chowdhury P; Pastan I
Mol Cancer Ther; 2001 Dec; 1(2):79-84. PubMed ID: 12467225
[TBL] [Abstract][Full Text] [Related]
11. Modulating mesothelin shedding to improve therapy.
Pastan I; Zhang Y
Oncotarget; 2012 Feb; 3(2):114-5. PubMed ID: 22337812
[No Abstract] [Full Text] [Related]
12. Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line.
Hollevoet K; Mason-Osann E; Müller F; Pastan I
PLoS One; 2015; 10(3):e0122462. PubMed ID: 25803818
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
Hassan R; Sharon E; Thomas A; Zhang J; Ling A; Miettinen M; Kreitman RJ; Steinberg SM; Hollevoet K; Pastan I
Cancer; 2014 Nov; 120(21):3311-9. PubMed ID: 24989332
[TBL] [Abstract][Full Text] [Related]
14. Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors.
Mazor R; Zhang J; Xiang L; Addissie S; Awuah P; Beers R; Hassan R; Pastan I
Mol Cancer Ther; 2015 Dec; 14(12):2789-96. PubMed ID: 26443804
[TBL] [Abstract][Full Text] [Related]
15. Isolation and characterizations of a novel recombinant scFv antibody against exotoxin A of Pseudomonas aeruginosa.
Shadman Z; Farajnia S; Pazhang M; Tohidkia M; Rahbarnia L; Najavand S; Toraby S
BMC Infect Dis; 2021 Mar; 21(1):300. PubMed ID: 33761869
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas.
Li Q; Verschraegen CF; Mendoza J; Hassan R
Anticancer Res; 2004; 24(3a):1327-35. PubMed ID: 15274292
[TBL] [Abstract][Full Text] [Related]
17. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
Gubbels JA; Belisle J; Onda M; Rancourt C; Migneault M; Ho M; Bera TK; Connor J; Sathyanarayana BK; Lee B; Pastan I; Patankar MS
Mol Cancer; 2006 Oct; 5(1):50. PubMed ID: 17067392
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
Hassan R; Ebel W; Routhier EL; Patel R; Kline JB; Zhang J; Chao Q; Jacob S; Turchin H; Gibbs L; Phillips MD; Mudali S; Iacobuzio-Donahue C; Jaffee EM; Moreno M; Pastan I; Sass PM; Nicolaides NC; Grasso L
Cancer Immun; 2007 Dec; 7():20. PubMed ID: 18088084
[TBL] [Abstract][Full Text] [Related]
19. Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.
Cerise A; Bera TK; Liu X; Wei J; Pastan I
Clin Colorectal Cancer; 2019 Sep; 18(3):192-199.e1. PubMed ID: 31345777
[TBL] [Abstract][Full Text] [Related]
20. HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy.
Xiang X; Feng M; Felder M; Connor JP; Man YG; Patankar MS; Ho M
J Cancer; 2011; 2():280-91. PubMed ID: 21611109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
